Gene therapy vector design strategies for the treatment of cancer

Future Oncology

Volumn 1, Issue 3, 2005, Pages 361-373

  Dong, John Y ^a,b   Woraratanadharm, Jan ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GenPhar Inc   (United States)

Author keywords

adenovirus; amplification feedback loop; differentially suppressible tetracyclinregulated expression system; dl1520; gene therapy; Onyx 015; positive feedback loop with prostate specificity; SCH 58500

Indexed keywords

ANIMAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW; TRANSGENE;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; TRANSGENES;

EID: 33646455930     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.3.361     Document Type: Review

References (49)

1. Asai A, Miyagi Y, Sugiyama A et al.: Negative effects of wild type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J. Neurooncol. 19(3), 259-268 (1994).
2. Carbone DP, Minna JD: In vivo gene therapy of human lung cancer using wild type p53 delivered by retrovirus. J. Natl Cancer Inst. 86(19), 1437-1438 (1994).
3. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA: Therapeutic effect of a retroviral wild type p53 expression vector in an orthotopic lung cancer model. J. Natl Cancer Inst. 86(19), 1458-1462 (1994).
4. Rosenfeld MR, Meneses P, Dalmau J, Drobnjak M, Cordon-Cardo C, Kaplitt MG: Gene transfer of wild type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Neurology 45(8), 1533-1539 (1995).
5. Santoso JT, Tang DC, Lane SB et al.: Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol. Oncol. 59(2), 171-178 (1995).
6. Yang C, Cirielli C, Capogrossi MC, Passaniti A: Adenovirus-mediated wild type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 55(19), 4210-4213 (1995).
7. Zeimet AG, Marth C: Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4(7), 415-422 (2003).
8. Alberts SR, Schroeder M, Erlichman C et l.: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II trial. J. Clin. Oncol. 22(24), 4944-4950 (2004).
9. Chanan-Khan AA: Bcl-2 antisense therapy in multiple myeloma. Oncology (Huntingt.) 18(13 Suppl. 10), 21-24 (2004).
10. Rubinchik S, Ding R, Qiu AJ, Zhang F, Dong J: Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther. 7(10), 875-885 (2000).
11. Rubinchik S, Wang D, Yu H et al.: A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol. Ther. 4(5), 416-426 (2001).
12. Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY: Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 10(11), 814-822 (2003).
13. Norris JS, Hyer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S, Dong JY: The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr. Gene Ther. 1(1), 123-136 (2001).
14. Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS: Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 8(18), 1363-1371 (2001).
15. Satoh T, Irie A, Egawa S, Baba S: In situ gene therapy for prostate cancer. Curr. Gene Ther. 5(1), 111-119 (2005).
16. Yazawa K, Fisher WE, Brunicardi FC: Current progress in suicide gene therapy for cancer. World J. Surg. 26(7), 783-789 (2002).
17. Alvarez RD, Gomez-Navarro J, Wang M et al.: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther. 2, 524-2530 (2000).
18. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl J. Med. 333(26), 1757-1763 (1995).
19. Yano S, Nishioka Y, Goto H, Sone S: Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci. 94(6), 479-485 (2003).
20. Isayeva T, Kumar S, Ponnazhagan S: Antiangiogenic gene therapy for cancer (review). Int. J. Oncol. 25(2), 335-343 (2004).
21. Tandle A, Blazer DG, Libutti SK: Antiangiogenic gene therapy of cancer: recent developments. J. Transl. Med. 2(1), 22 (2004).
22. Rainov NG, Ren H: Oncolytic viruses for treatment of malignant brain tumors. Acta Neurochir. Suppl. 88, 113-123 (2003).
23. Ries SJ, Brandts CH: Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov. Today 9(17), 759-768 (2004).
24. Johannes L: Onxy therapy shows promise against tumors. (Onyx Pharmaceuticals, Inc.s Onyx-015, a cancer therapy). The Wall Street J. B8 (August 1, 2000).
25. Chen Y, DeWeese T, Dilley J et al.: CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 61(14), 5453-5460 (2001).
26. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR: The addition of adenovirus Type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59(17), 4200-4203 (1999).
27. Miyatake S: Gene therapy using tissuespecific replication competent HSV. Hum. Cell. 15(3), 130-137 (2002).
28. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D: Part I: Vaccines for solid tumors. Lancet Oncol. 5(11), 681-689 (2004).
29. Mocellin S, Semenzato G, Mandruzzato S, Riccardo Rossi C: Part II: Vaccines for haematological malignant disorders. Lancet Oncol. 5(12), 727-737 (2004).
30. Gao JQ, Sugita T, Kanagawa N et al.: A single intratumoral injection of a fibremutant adenoviral vector encoding interleukin-12 induces remarkable antitumor and antimetastatic activity in mice with Meth-A fibrosarcoma. Biochem. Biophys. Res. Commun. 328(4), 1043-1050 (2005).
31. Becard N, de Revel T, Sorg T, Dormont D, Le Grand R: Expression of human IL-1á after intramarrow gene transfer into healthy non-human primate by adenoviral vector. J. Med. Primatol. 34(1), 1-12 (2005).
32. De B, Heguy A, Leopold PL et al.: Intrapleural administration of a serotype 5 adeno-associated virus coding for á1- antitrypsin mediates persistent, high lung and serum levels of á1-antitrypsin. Mol. Ther. 10(6), 1003-1010 (2004).
33. Sandrin V, Russell SJ, Cosset FL: Targeting retroviral and lentiviral vectors. Curr. Top. Microbiol. Immunol. 281, 137-178 (2003).
34. Curiel DT: Strategies to adapt adenoviral vectors for targeted delivery. Ann. NY Acad. Sci. 886, 158-171 (1999).
35. Kasahara N, Dozy AM, Kan YW: Tissuespecific targeting of retroviral vectors through ligand-receptor interactions. Science 266(5189), 1373-1376 (1994).
36. Chu TH, Martinez I, Sheay WC, Dornburg R: Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther. 1(5), 292-299 (1994).
37. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ: Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248(1-2), 47-66 (2001).
38. Rots MG, Curiel DT, Gerritsen WR, Haisma HJ: Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J. Control Release 87(1-3), 159-165 (2003).
39. Snitkovsky S, Niederman TM, Carter BS, Mulligan RC, Young JA: A TVA-singlechain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor. J. Virol. 74(20), 9540-9545 (2000).
40. Haviv YS, Curiel DT: Conditional gene targeting for cancer gene therapy. Adv. Drug Deliv. Rev. 53(2), 135-154 (2001).
41. Woraratanadharm J, Rubinchik S, Yu H, Fan F, Morrow SM, Dong JY: Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop. Gene Therapy 11(18), 1399-1407 (2004).
42. Zhang D, Sutanto EN, Rakoczy PE: Concurrent enhancement of transcriptional activity and specificity of a retinal pigment epithelial cell-preferential promoter. Mol. Vis. 10, 208-14 (2004).
43. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 89(12), 5547-5551 (1992).
44. Ray S, Paulmurugan R, Hildebrandt I et al.: Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum. Gene Ther. 15(7), 681-690 (2004).
45. Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, Norris JS: Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 10(4), 330-339 (2003).
46. Hyer ML, Sudarshan S, Kim Y et al.: Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fasmediated apoptosis. Cancer Biol. Ther. 1(4), 401-406 (2002).
47. Hacein-Bey-Abina S, Le Deist F, Carlier F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346(16), 1185-1193 (2002).
48. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003).
49. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348(3), 255-256 (2003).